首页> 外文期刊>BMC Geriatrics >Psychotropic and anti-dementia treatment in elderly persons with clinical signs of dementia with Lewy bodies: a cross-sectional study in 40 nursing homes in Sweden
【24h】

Psychotropic and anti-dementia treatment in elderly persons with clinical signs of dementia with Lewy bodies: a cross-sectional study in 40 nursing homes in Sweden

机译:路易氏体痴呆临床症状老年人的精神和抗痴呆治疗:瑞典40所养老院的横断面研究

获取原文
       

摘要

Elderly persons with a dementia diagnosis often suffer from different neuropsychiatric symptoms (NPS) such as delusions, hallucinations, depression, anxiety, irritability and agitation. Currently, the medical treatment for NPS consists mostly of psychotropic medication such as hypnotics/sedatives, anxiolytics and antipsychotics. In elderly persons with dementia, usage of antipsychotics is less appropriate because of the risk of side effects such as parkinsonism, rapid cognitive decline, cerebrovascular events and finally mortality. Furthermore, elderly persons with dementia with Lewy bodies (DLB) are often hypersensitive to antipsychotics with numerous serious adverse events such as somnolence, sedation, extra-pyramidal symptoms, delirium and increased mortality. The aim of this study was to investigate the usage of psychotropics with a focus on antipsychotics and anti-dementia medication (according to the Anatomical Therapeutic Chemical Classification System) in elderly persons with clinical signs of DLB living in dementia nursing homes (NHs) in Sweden. Between 2012 and 2013, we applied a specially designed questionnaire that covered the clinical DLB features according to the consensus criteria of DLB. We also collected computerized medical lists from the Swedish National Medication Dispensing System from the same period. All dementia NHs (n?=?40) in Malm?, the third largest city in Sweden, were covered. Of 650 eligible residents, 610 (94%) were included with 576 medical lists. The mean age was 86?years and 76% were women. Treatment with antipsychotics was seen in 22% of residents, hypnotics/sedatives in 41%, antidepressants in 50% and anxiolytics in 58%. We also found an increasing usage of antipsychotics from 25% to 43% in residents with the increasing number of DLB features. Anti-dementia medications were found in 45% of the elderly with a dementia diagnosis. However, residents with two or more DLB features had less anti-dementia medication (37%) than the rest of the dementia-diagnosed NH residents (62–69%). Residents with 2–4 DLB clinical features in Swedish NHs receive an unfavourable medical treatment with high antipsychotic usage and insufficient anti-dementia medication. These findings show the importance of identifying elderly persons with DLB features more effectively and improving the collaboration with nursing care to provide better medical prescription.
机译:诊断为痴呆症的老年人通常会遭受不同的神经精神症状(NPS),如妄想,幻觉,抑郁,焦虑,易怒和躁动。当前,用于NPS的药物主要包括精神药物,例如催眠药/镇静药,抗焦虑药和抗精神病药。在老年痴呆症患者中,抗精神病药的使用不太合适,因为它具有副作用的风险,如帕金森氏病,快速认知能力下降,脑血管事件以及最终死亡。此外,患有路易体痴呆(DLB)的老年人通常对抗精神病药过敏,并伴有许多严重的不良事件,例如嗜睡,镇静,锥体束外症状,del妄和死亡率增加。这项研究的目的是调查居住在瑞典痴呆症护理院(NHs)中具有DLB临床症状的老年人对精神药物的使用,重点是抗精神病药和抗痴呆药(根据解剖化学分类法) 。在2012年至2013年之间,我们根据DLB的共识标准应用了专门设计的问卷,涵盖了DLB的临床特征。我们还从同期的瑞典国家药物配发系统中收集了计算机化的医疗清单。覆盖了瑞典第三大城市马尔姆的所有老年痴呆症NHs(n = 40)。在650名合格居民中,有610名医疗名单中包括610名(94%)。平均年龄为86岁,女性为76%。 22%的居民使用抗精神病药物治疗,41%的患者使用催眠药/镇静剂,50%的患者使用抗抑郁药,58%的患者使用抗焦虑药。我们还发现,随着DLB功能数量的增加,居民中抗精神病药的使用率从25%增加到43%。在患有痴呆症诊断的老年人中发现了45%的抗痴呆药物。但是,具有两个或多个DLB功能的居民抗痴呆药物的使用率(37%)比痴呆诊断为NH的其他居民(62-69%)要少。瑞典NHs中具有2-4种DLB临床特征的居民,由于抗精神病药的使用率高且抗痴呆药物治疗不足而受到不利的药物治疗。这些发现表明了更有效地识别具有DLB功能的老年人以及改善与护理合作以提供更好的医疗处方的重要性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号